Evaluating Stereotactic Radiotherapy for Brain Metastases
Stereotactic Radiotherapy Management of Brain Metastases: the Value of a Longitudinal Multimodal Approach
This study is testing if a new type of targeted radiation therapy for brain metastases works better than the usual whole-brain radiation for cancer patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 700 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Brest Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Brest) |
| Trial ID | NCT06029140 on ClinicalTrials.gov |
What this trial studies
This study focuses on the management of brain metastases in cancer patients, particularly evaluating the effectiveness of stereotactic radiotherapy (SRT) compared to traditional whole-brain radiotherapy. It aims to assess the impact of early imaging assessments on patient outcomes, including recurrence-free survival and overall survival. Additionally, the study will explore the diagnostic capabilities of DOPA PET and multimodal MRI in identifying radionecrosis. The goal is to improve monitoring and management strategies for patients with brain metastases.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with solid cancers that have metastasized to the brain, treated with hypofractionated external stereotactic radiotherapy.
Not a fit: Patients with primary brain tumors or those treated with conventional radiotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and treatment strategies for patients with brain metastases, potentially enhancing survival and quality of life.
How similar studies have performed: Previous studies have shown success with stereotactic radiotherapy for brain metastases, indicating that this approach is well-supported by existing research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Patients with solid cancer with brain metastases treated by hypofractionated external stereotactic radiotherapy at the CHRU de Brest between 01/01/2014 and 31/12/2022 * Patient affiliated to a social security scheme Exclusion Criteria: * Patients with primary brain tumors * Patients treated with normofractionated external cerebral radiotherapy * Age \< 18 years * Patients under legal protection (guardianship, curatorship, etc.)
Where this trial is running
Brest
- Chu Brest — Brest, France (Recruiting)
Study contacts
- Principal investigator: Vincent Bourbonne, MD, PhD — Radiation Oncology Department, Brest University Hospital
- Study coordinator: Vincent BOURBONNE, MD, PhD
- Email: vincent.bourbonne@chu-brest.fr
- Phone: +33298223398
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.